Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.
Heat shock protein (Hsp)90 serves as a chaperone protein that promotes the proper folding of proteins involved in a variety of signal transduction processes involved in cell growth. Hsp90 inhibitors, which inhibit the activity of critical client proteins, have emerged as the accessory therapeutic agents for multiple human cancer types. To better understand the effects of Hsp90 inhibitors in cancer treatment, the present study reviewed 15 published phase II clinical trials to investigate whether Hsp90 inhibitors will benefit patients with cancer. Information of complete response, partial response, stable disease, objective response and objective response rate was collected to evaluate clinical outcomes. Overall, Hsp90 inhibitors are effective against a variety of oncogene-addicted cancers, including those that have developed resistance to specific receptors.
Department of Oncology, The Third Affiliated Hospital of Nanjing Medical University, Nanjing 211100, P.R. China.
He
H
Wang
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China.
Mingjie
M
Lu
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China.
Mengqian
M
Yao
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China.
Wei
W
Zhu
Hsp90 inhibitor; clinical trial; genotype; tumor